Ghrelin Effect on Beta Cell Function in Health and Disease

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-04-30

Study Completion Date

2014-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To determine the role of nutrient status on ghrelin regulation of insulin secretion. We hypothesize that ghrelin and glucagon-like peptide-1 (GLP-1)(both are hormones made in the gut,) have differential effects on β-cell function in the fed state. We will compare insulin secretion and glucose turnover during meal ingestion using a dual glucose tracer and mixed meal protocol in subjects receiving ghrelin or saline. We will also determine the role of ghrelin-stimulated GLP-1 levels in this process using the GLP-1 receptor (GLP-1R) antagonist Exendin(9-39) (Ex-9).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans

NCT01900340

Appetite and General Nutritional Disorders

COMPLETED PHASE1

Ghrelin and Beta Cell Function in Diabetes

NCT02440061

Type 2 Diabetes Mellitus

WITHDRAWN PHASE1

Glucagon Modulation of Ghrelin Secretion

NCT00929812

Healthy Subjects Obesity Diabetes Mellitus, Type 1

UNKNOWN PHASE3

A Dose-response Study Examining the Contribution of GLP-1 Receptor Signaling to Glucagon-stimulated Insulin Secretion

NCT04459338

Healthy

COMPLETED PHASE3

Deacylated Ghrelin and Beta Cell Function

NCT01531283

the Diabetic Process

UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

We plan to study 20 healthy subjects on 4 occasions where they will receive ghrelin, ghrelin+Ex-9, Ex-9 or saline infusion after an overnight fast in a randomized order; Ex-9 will be used to block GLP-1 action. A 240-minute meal tolerance test (MTT) using a dual glucose tracer method will serve as the foundation of each study visit. One tracer, \[6,6-2H2\]glucose will be infused intravenously before and during the test meal to quantify fasting endogenous glucose production (EGP), and glucose disappearance during the meal. A second tracer, \[U-13C\]glucose, will be included in the meal to trace the appearance of oral glucose. The systemic appearance rates of both ingested tracer and total (i.e., ingested and endogenously produced) glucose will be calculated. Using this protocol, we will be able to evaluate a) insulin secretion in response to mixed-meal ingestion, b) glucose appearance and glucose disappearance during meal ingestion, c) the ghrelin effect on these parameters without GLP-1, and d) the effect of GLP-1 in the response based on the effects with and without Ex-9.

This dual-tracer method has been used to assess the ability of an individual to dispose of an oral glucose load, and accurately fractionates the appearance of ingested glucose in plasma (Ra meal), EGP, and peripheral glucose disposal (Rd) in this setting 41-42. The \[6,6-2H2\]glucose and \[U-13C\]glucose are stable-isotope tracers and are different from radioactive-isotope tracers in that they do not emit radiation.

All procedures will be performed at the CTRC at the Cincinnati Children's Hospital Medical Center (CCHMC).

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

saline

Saline: 0.9% saline solution

Group Type PLACEBO_COMPARATOR

saline

Intervention Type DRUG

ghrelin and exendin (9-39)

Ghrelin+Ex-9: Combination of ghrelin and Ex-9,

Group Type EXPERIMENTAL

Exendin (9-39)

Intervention Type DRUG

acyl ghrelin

Intervention Type DRUG

Exendin (9-39)

Exendin (9-39) (25 µg/kg) bolus over 1 min followed by a continuous infusion of 2.5 µg/kg/min

Group Type EXPERIMENTAL

Exendin (9-39)

Intervention Type DRUG

ghrelin

synthetic human Acyl Ghrelin (0.28 μg/kg) bolus over 1 min followed by 2 μg/kg/h continuous infusion,

Group Type EXPERIMENTAL

acyl ghrelin

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Exendin (9-39)

Intervention Type DRUG

acyl ghrelin

Intervention Type DRUG

saline

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Healthy men and women
2. Ages between 18 and 45 years
3. BMI between 18 and 29 kg/m2

Exclusion Criteria

1. History or clinical evidence of impaired fasting glucose or diabetes mellitus, myocardial infarction within the past year, history or symptoms of congestive heart failure, uncontrolled hypertension, history or active liver or renal disease (AST or ALT \>2x upper limits of normal, calculated glomerular filtration rate \[GFR\] \<60).
2. History of pituitary or adrenal disorders or neuroendocrine tumor.
3. Anemia defined as hematocrit \<33%.
4. Use of medications that alter glucose metabolism
5. Pregnancy or lactation.
6. Abnormal Electrocardiogram (ECG): evidence of ischemia or arrhythmia.
7. Women who have a positive pregnancy test at any time during the study period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes